Zeta CD38 Antibody. Zeta’s recombinant rabbit antibody recognizes CD38, a transmembrane protein that is highly expressed on thymocytes. CD38 is also present on activated T-cells and terminally differentiated B-cells (plasma cells) and other reactive cells include NK cells, monocytes, macrophages and dendritic cells. CD38 may be detected on cells from multiple myeloma, ALL (B and T) and some AML.
CD38 is a marker of cellular activation expressed by plasma cells, T cells, NK cells and other hematopoietic cell types during various stages of maturation. CD38 is also a marker of activation that is present on many hematopoietic cells, especially plasma cells. CD38 expression in lymphoid neoplasms is not specific for any discrete disease entity and can be aberrantly expressed in carcinoma and melanoma. The absence of CD38 (CD38-/CD34+) is used as a marker for bone marrow hematopoietic stem cells and chronic lymphocytic leukemia with CD38 expression is associated with a more aggressive clinical course and shorter overall survival. Hairy cell leukemia with CD38 expression is associated with a more aggressive clinical course. Acute myeloid leukemia with CD38 expression was shown to be associated with a favorable prognosis and high numbers of immature (CD34+/CD38-) blasts in myeloid leukemia are associated with unfavorable prognosis. CD38 expression on multiple myeloma cells has been correlated to anti-CD38 treatment response. In the future, CD38 expression in tissue sections may be used to monitor anti-CD38 therapy with therapeutic antibodies for early detection of treatment resistance (loss of CD38 expression).
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.